Microchip implanted in tumors could reveal best drug for each patient

NCT ID NCT05700461

Recruiting now Knowledge-focused Sponsor: Oliver Jonas Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study tests a small implantable device that releases tiny amounts of up to 19 different cancer drugs directly into a kidney tumor. The goal is to see if the device is safe and can help predict which drug works best for each patient. About 20 adults with kidney cancer who are already scheduled for surgery will receive the implant before their tumor is removed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Implantable Microdevice (IMD) with standard-of-care drugs
What this could lead to: If successful, this device could help doctors quickly identify the most effective drug for each patient's kidney cancer, personalizing treatment.
What could go wrong: This is a very early, small pilot study focused on safety and feasibility, not effectiveness. The device may not work as hoped or could cause side effects from implantation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER METASTATIC RENAL CELL CARCINOMA RENAL CELL CARCINOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.